Adult ADHD - Strattera Grows Up

Introduction

With the recent medical classification of adult ADHD and potentially twice the number of patients compared to pediatric ADHD, manufacturers are seeking new indications in this expanding and lucrative market. Lilly’s Strattera was the first drug to exploit this, and is forecast to reach blockbuster status by 2006. Consequently, manufacturers will need to differentiate their products from Strattera.

Scope

• Overview of the epidemiology of adult ADHD, with an assessment of the untapped patient potential
• Discussion of the problems facing physicians in the diagnosis of adult ADHD
• Analysis of the current market leaders and primary contenders for market entry, with adult ADHD-specific market forecasts
• Exploration of product positioning and life-cycle management strategies currently used by Strattera, Adderall XR and Concerta

Highlights

Strattera was the first drug approved for the treatment of adult ADHD in November 2002. Since launch Strattera has a steady sales increase from $55m in Q1 2003 to $133m in Q4 2003, and Datamonitor has forecast Strattera to reach blockbuster status by 2006.

Shire’s Adderall XR recently received an approvable letter from the FDA for adult ADHD and J&J’s Concerta is currently in Phase III with an expected launch in 2005. Datamonitor forecasts that both drugs will see an increase in sales from gaining an indication for this market, although both will also experience a decline in revenues post 2005.

Approximately 75% of adults with ADHD present with a comorbid condition, of which anxiety and depressive disorders predominate. Datamonitor has highlighted two drug classes, which may benefit from further investigation of the treatment of such comorbidities in order to increase their market share in the adult ADHD market.

Reasons to Purchase

• Analyze the commercial viability of the adult ADHD market, based on estimated patient numbers
• Develop market entry and consolidation strategies through an understanding of key unmet needs in the market
• Identify and assess novel R&D compounds in the adult ADHD pipeline